Micafungin Pharmazac

Micafungin, the active ingredient in Micafungin Pharmazac, is an echinocandin presented as an intravenous formulation for infusion use. It treats serious systemic and esophageal Candida infections and is used for prophylaxis in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungin Pharmazac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal used to treat and prevent invasive Candida infections. - Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections in immunocompromised patients. - Candida esophagitis: eradication of esophageal Candida lesions causing pain and dysphagia. - Candida peritonitis: management of intra‑abdominal Candida infection following surgery or peritoneal dialysis. - Candida meningitis: therapy for fungal meningitis caused by Candida species. - Prophylaxis in hematopoietic stem cell transplantation: prevention of invasive fungal disease in transplant recipients.

Micafungin may cause a range of adverse reactions, most of which are mild to moderate, while rare events can be severe.

Common Side Effects: - Fever: transient elevation of body temperature during or after infusion. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing or pressure sensation. - Rash: skin redness or mild eruption. - Elevated liver enzymes: transient increase in ALT or AST. - Infusion‑related reactions: flushing, chills, or mild hypotension.

Serious or Rare Side Effects: - Hepatic failure: significant liver injury requiring monitoring. - Severe allergic reactions: anaphylaxis or angioedema. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: extensive skin detachment. - Neutropenia: marked reduction in white blood cells. - Renal impairment: acute kidney injury in susceptible patients.

Prior to initiating Micafungin therapy, clinicians should consider several safety measures to minimize risk. - Hepatic function: monitor liver enzymes before and during treatment. - Renal function: assess kidney function, especially in patients with pre‑existing impairment. - Drug interactions: review concomitant medications that affect hepatic metabolism. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Infusion monitoring: administer under medical supervision and observe for hypersensitivity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly lower micafungin exposure. - Co‑administration with other echinocandins: duplicate antifungal therapy should be avoided. - High‑dose cyclosporine: can increase micafungin plasma concentrations.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may increase risk of hepatotoxicity. - Warfarin: monitor INR as micafungin may affect anticoagulant metabolism. - Immunosuppressants (e.g., tacrolimus): observe blood levels for possible alterations.